Novo Nordisk

News

ESC: Real-world study gives Wegovy edge over Lilly rival

Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy works better than Eli Lilly's fast-growing rival Zepbound.

News

Novo reels in Replicate for new cardiometabolic drugs

Replicate will receive up to $550m from Novo Nordisk in an alliance that aims to deliver a new generation of drugs for obesity and diabetes.

News

Diabetics on Lilly's orforglipron shed 10.5% of their weight

Eli Lilly has reported the results of a third phase 3 trial of oral weight-loss therapy orforglipron, clearing the way for filings before year-end.

News

Novo Nordisk cuts GLP-1 prices for cash buyers

Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.

News

Novo Nordisk claims first GLP-1 approval in MASH

Under pressure from rivals in the GLP-1 space, Novo Nordisk has been given a leg-up with a first-in-class approval for Wegovy in liver disease MASH.

News

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

ESC: Real-world study gives Wegovy edge over Lilly rival

Novo reels in Replicate for new cardiometabolic drugs

Diabetics on Lilly's orforglipron shed 10.5% of their weight

Novo Nordisk cuts GLP-1 prices for cash buyers

Novo Nordisk claims first GLP-1 approval in MASH

Novo Nordisk weakens again on interim results readout

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks